CA3176498A1 - Nouvelle combinaison pour le traitement du sida - Google Patents

Nouvelle combinaison pour le traitement du sida Download PDF

Info

Publication number
CA3176498A1
CA3176498A1 CA3176498A CA3176498A CA3176498A1 CA 3176498 A1 CA3176498 A1 CA 3176498A1 CA 3176498 A CA3176498 A CA 3176498A CA 3176498 A CA3176498 A CA 3176498A CA 3176498 A1 CA3176498 A1 CA 3176498A1
Authority
CA
Canada
Prior art keywords
ifn
agent
cells
interferon
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176498A
Other languages
English (en)
Inventor
Daniel Zagury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
21c Bio
Original Assignee
21c Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/857,715 external-priority patent/US20210332127A1/en
Application filed by 21c Bio filed Critical 21c Bio
Publication of CA3176498A1 publication Critical patent/CA3176498A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une nouvelle méthode de traitement du syndrome d'immunodéficience acquise (SIDA) chez un sujet nécessitant un tel traitement. En particulier, ladite méthode consiste à administrer une combinaison, une trousse d'éléments, une composition ou une composition pharmaceutique comprenant un agent bloquant l'interféron de type III, un agent bloquant l'interféron-alpha (IFN-?), un agent antirétroviral (ART) et, éventuellement, un agent bloquant l'interféron-bêta (IFN-?) et/ou un agent d'inversion de latence (LRA).
CA3176498A 2020-04-24 2021-04-23 Nouvelle combinaison pour le traitement du sida Pending CA3176498A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16/857,715 US20210332127A1 (en) 2020-04-24 2020-04-24 Novel combination for the treatment of aids
US16/857,715 2020-04-24
EP20305405.1 2020-04-24
EP20305405 2020-04-24
PCT/EP2021/060738 WO2021214321A1 (fr) 2020-04-24 2021-04-23 Nouvelle combinaison pour le traitement du sida

Publications (1)

Publication Number Publication Date
CA3176498A1 true CA3176498A1 (fr) 2021-10-28

Family

ID=75660047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176498A Pending CA3176498A1 (fr) 2020-04-24 2021-04-23 Nouvelle combinaison pour le traitement du sida

Country Status (3)

Country Link
EP (1) EP4138910A1 (fr)
CA (1) CA3176498A1 (fr)
WO (1) WO2021214321A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134202A1 (fr) * 2015-02-20 2016-08-25 The Johns Hopkins University Combinaisons de médicaments pour le traitement du vih
US11136399B2 (en) * 2016-07-14 2021-10-05 Institute Of Biophysics, Chinese Academy Of Sciences Type I interferon receptor antibody and use thereof
WO2018081197A1 (fr) * 2016-10-27 2018-05-03 The University Of North Carolina At Chapel Hill Modulation d'interférons de type i pour réactiver le réservoir du vih -1 et améliorer le traitement du vih -1
US11690895B2 (en) * 2017-10-13 2023-07-04 Meiogen Biotechnology Corporation Compositions and methods of interferon alpha binding proteins

Also Published As

Publication number Publication date
EP4138910A1 (fr) 2023-03-01
WO2021214321A1 (fr) 2021-10-28

Similar Documents

Publication Publication Date Title
Doyle et al. HIV-1 and interferons: who's interfering with whom?
CN110088623B (zh) 选择用于治疗免疫病症的高效干细胞的方法
US20200172864A1 (en) T Cell Expansion Method
EP3972645A1 (fr) Procédés d'identification de patients atteints du vih sensibles à une thérapie avec des anticorps dirigés contre le glycane v3 de la gp120
CA3176498A1 (fr) Nouvelle combinaison pour le traitement du sida
US20210332127A1 (en) Novel combination for the treatment of aids
WO2020109328A1 (fr) Traitement combiné d'infections au vih
JP7303631B2 (ja) 膜受容体への結合による抗ウイルス免疫療法
Zhao et al. Alterations of the frequency and functions of follicular regulatory T cells and related mechanisms in HIV infection
US20220144923A1 (en) METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2017177175A1 (fr) Procédés et compositions ciblant une latence rétrovirale
WO2017064558A1 (fr) Nouveau immunostimulant
Haring et al. Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease
US20230210984A1 (en) Adoptive immunotherapy
Kleinman SIV Reactivation from Latency in Virally Suppressed Macaques Using the HDACi Romidepsin and Cyclophosphamide
Forsyth Manipulation of host signalling for the characterisation and control of dengue fever
Lindahl Herpesvirus infections in transplant recipients
Castellví Characterization of cellular factors involved in HIV-1 pathogenesis with potential therapeutic implications in viral infections and cancer
Schweitzer Improving anti-viral T cell therapies by knockout of the NR4A family of transcription factors
Brisseau Impact of CCR5∆ 32/∆ 32 Allogenic Hematopoietic Stem Cell Transplant on Adaptive Immune Parameters in HIV Infection
Burton Host regulation of Epstein-Barr virus life cycle
Li TMEM203 is a putative co-receptor of innate immune adaptor protein STING
Cha Studies of T cell and B cell dysfunction induced by IFN-α in HIV-1 infection
Fogle T regulatory Cell Suppression of CD8+ Lymphocyte Responses During FIV Infection.
CN116510020A (zh) 降低ccr2含量或活性的物质在治疗或预防发热伴血小板减少综合征中的应用